Interestingly, several studies have shown that APR‐246 treatment leads to an increased xCT protein level in tumor cells (Ali et al, 2016; Liu et al, 2017; Lisek et al, 2018; Synnott et al, 2018), possibly due to its inhibition of mutant p53‐NRF2 complexing and/or its pro‐oxidant activities (Walerych et al, 2016; Eriksson et al, 2019). The gene discussed is SLC7A11; the disease is neoplasm.